Singh Nishita, Kashani Nima, Zea Vera Alonso G, Tkach Aleksander, Ganesh Aravind
Department of Internal Medicine (NS), Neurology Division, University of Manitoba, Winnipeg, Canada; Department of Clinical Neurosciences (NS, NK, AG), University of Calgary, Alberta, Canada; Department of Diagnostic and Interventional Neuroradiology (NK), Royal University Hospital, University of Saskatchewan, Saskatoon, Canada; Division of Neurology (AGZV), Children's National Hospital, Washington, DC; and Kelowna General Hospital (AT), University of British Columbia, Canada.
Neurol Clin Pract. 2024 Aug;14(4):e200317. doi: 10.1212/CPJ.0000000000200317. Epub 2024 May 31.
With recent trials suggesting that endovascular thrombectomy (EVT) alone may be noninferior to combined intravenous thrombolysis (IVT) with alteplase and EVT and that tenecteplase is non-inferior to alteplase in treating acute ischemic stroke, we sought to understand current practices around the world for treating acute ischemic stroke with large vessel occlusion (LVO) depending on the center of practice (IVT-capable vs IVT and EVT-capable stroke center).
The electronic survey launched by the Practice Current section of Neurology: Clinical Practice included 6 clinical and 8 demographic questions. A single-case scenario was presented of a 65-year-old man presenting with right hemiplegia with aphasia with a duration of 1 hour. Imaging showed left M1-MCA occlusion with no early ischemic changes. The respondents were asked about their treatment approach in 2 settings: the patient presented to (1) the IVT-only capable center and (2) the IVT and EVT-capable center. They were also asked about the thrombolytic agent of choice in current and ideal circumstances for these settings.
A total of 203 physicians (42.9% vascular neurologists) from 44 countries completed the survey. Most participants (55.2%) spent ≥50% of their time delivering stroke care. The survey results showed that in current practice, more than 90% of respondents would offer IVT + EVT to patients with LVO stroke presenting to either an EVT-capable (91.1%) or IVT-only-capable center (93.6%). Although nearly 80% currently use alteplase for thrombolysis, around 60% would ideally like to switch to tenecteplase independent of the practice setting. These results were similar between stroke and non-stroke neurologists.
Most physicians prefer IVT before EVT in patients with acute ischemic stroke attributable to large vessel occlusion independent of the practice setting.
近期试验表明,单纯血管内血栓切除术(EVT)可能不劣于联合使用阿替普酶的静脉溶栓(IVT)与EVT,且替奈普酶在治疗急性缺血性卒中方面不劣于阿替普酶。我们试图了解世界各地根据实践中心(具备IVT能力的卒中中心与具备IVT和EVT能力的卒中中心)治疗伴有大血管闭塞(LVO)的急性缺血性卒中的当前做法。
《神经病学:临床实践》“当前实践”板块发起的电子调查包含6个临床问题和8个人口统计学问题。呈现了一个单病例场景,一名65岁男性,出现右侧偏瘫伴失语1小时。影像学显示左侧大脑中动脉M1段闭塞,无早期缺血改变。询问受访者在两种情况下的治疗方法:患者就诊于(1)仅具备IVT能力的中心和(2)具备IVT和EVT能力的中心。还询问了他们在当前和理想情况下针对这些情况选择的溶栓药物。
来自44个国家的203名医生(42.9%为血管神经病学家)完成了调查。大多数参与者(55.2%)将≥50%的时间用于提供卒中治疗。调查结果显示,在当前实践中,超过90%的受访者会为就诊于具备EVT能力(91.1%)或仅具备IVT能力中心(93.6%)的LVO卒中患者提供IVT + EVT。尽管目前近80%的人使用阿替普酶进行溶栓,但约60%的人理想情况下希望无论实践环境如何都改用替奈普酶。卒中神经病学家和非卒中神经病学家的这些结果相似。
大多数医生在治疗由大血管闭塞导致的急性缺血性卒中患者时,无论实践环境如何,都倾向于在EVT之前进行IVT。